Object. Malignant gliomas are often highly invasive and can migrate along blood vessels. The purpose of the current study was to identify the substance in human serum and/or cerebrospinal fluid (CSF) that promotes glioma cell migration.
ALIGNANT gliomas have poor prognoses irrespective of treatment modality due to their propensity to migrate into and infiltrate the surrounding tissues, including the normal tissue surrounding the brain. 9 Thus, identification of molecules that promote glioma cell migration is critical and could help in the development of anti-invasion therapies.
The results of previous studies have shown that a variety of molecules promote glioma cell migration, including growth factors, 5, 15 extracellular matrix proteins, 11, 18 stromal cell derived factor-1␣, chemokines, 34 and lysophosphatidic acid-Rho A activating factor. 20, 28 The actual biological functions of these molecules in patients with malignant glioma, however, are not clear because most of the studies have been carried out in vitro or in animal models.
Vascular proliferation is a pathological feature of malignant invasive astrocytoma and GBM, 17 but it also must be recognized that invasion can occur without angiogenesis, such as occurs in diffuse, infiltrative gliomas. This invasiveness could be due to the presence of factors in serum and CSF that promote glioma cell survival and/or enhance invasion into the tissue surrounding the brain. These substances may also act as chemoattractants for tumor cells and influence the direction of migration. Indeed, extensive tumor cell movement along blood vessels or myelinated fiber tracts of white matter has been frequently observed in human glioma tissues. 10, 31 Also, high-molecular-weight serum proteins are known to promote glioma cell migration, 16, 19 although the active molecule has not been identified. Therefore, the purpose of the current study was to identify the substance in human serum and/or CSF that induces glioma cell migration.
Materials and Methods

Preparation of Human Serum and CSF
Venous blood samples were taken from eight patients with gliInduction of glioma cell migration by vitronectin in human serum and cerebrospinal fluid omas, one patient with a pituitary adenoma, and four healthy volunteers. All patients had growing tumors according to magnetic resonance imaging studies, and blood samples were taken preoperatively with written consent from the patients or their relatives. After centrifugation of the blood samples at 1500 G for 5 minutes, supernatants were collected, dialyzed against 25 mM phosphate buffer (pH 7.0) and sterilized using a syringe-driven 0.22-m filter unit (Millipore). The concentration of protein in serum samples was measured with a protein assay kit (Bio-Rad), and the serum samples were stored at Ϫ20˚C until use. In two of the four patients with glioma (the patients with anaplastic astrocytoma and gliomatosis cerebri), CSF samples were also taken after surgical removal of the tumor mass and/or invaded brain tissue and after completion of radiation therapy. The CSF samples were stored at Ϫ20˚C until use.
Cell Culture, Proteins, and Antibodies A172 human GBM cells (JCRB0228) and T98G human GBM cells (JCRB9041) were obtained from the Health Science Research Resources Bank (Osaka, Japan). The A172 cells were grown in DMEM containing 10% fetal bovine serum and the T98G cells were grown in minimal essential medium containing 10% fetal bovine serum, 1% sodium pyruvate, and 1% nonessential amino acids. Human vitronectin and human plasma fibronectin were purchased from Becton Dickinson. The following neutralizing monoclonal antibodies were purchased from Chemicon: AV1 for human integrin ␣v subunit, LM609 for integrin ␣v␤3, P1F6 for integrin ␣v␤5, and P1D6 for integrin ␣5 subunit. The murine anti-human vitronectin monoclonal antibodies for immunoblotting were purchased from Chemicon, and sheep anti-human vitronectin antibodies for immunodepletion were purchased from Cedarlane. Control mouse and sheep IgG was purchased from Sigma-Aldrich, Inc., and GRGDSP and GRGESP hexapeptides were purchased from AnaSpec, Inc.
Cell Migration Assay
Cell migration assays were performed in two-well Boyden chambers containing uncoated 8-m-pore polyethylene terephthalate membranes (Becton Dickinson). The upper filter surfaces were coated with 25 g of Matrigel (BD Biosciences) to facilitate the attachment and spreading of A172 cells because they did not fully attach and spread on uncoated membranes in serum-free conditions even after 20 hours. Trypsinized A172 cells were suspended in DMEM containing 0.1% bovine serum albumin and 5 mM hydroxyurea (to block mitosis) 4 and then applied to Matrigel-coated filters (10 4 cells in 100 l/well). The lower compartment of each well was filled with 500 l of DMEM containing human serum (300 g, approximately 1% serum) or CSF. After incubation at 37˚C for 20 hours in a humidified atmosphere containing 5% CO 2 , the cells on the upper surface of the filter were removed. The cells on the lower surface of the filter were fixed with 70% methanol, stained with Giemsa solution, and the cells that migrated to the lower side of the filter were counted using a stereomicroscope (MZ APO, Leica). Each sample was assayed in triplicate and two independent experiments were performed, except for the dose-response assay using CSF samples, which was performed only once because of the limited amount of CSF available. The migration assay using T98G cells was performed without the Matrigel coating because the coating was not needed for the full attachment and spreading of the cells. To examine the effects of integrin-neutralizing antibodies or RGD peptide, cell suspensions were incubated with antibodies (10 g/ml) or GRGDSP or GRGE-SP hexapeptides (50 g/ml) at room temperature for 15 minutes before they were plated on the filter. The results were expressed as a percentage of the value obtained using control IgG. The statistical significance of differences was determined using a two-tailed Student t-test.
Treatment of Human Serum With Heat or Trypsin
To inactivate serum proteins, normal human serum was heated at 100˚C for 10 minutes or incubated with 5 g trypsin at 37˚C for 30 minutes. Treated sera (300 g protein) were added to the lower compartments of the Boyden chambers, and cell migration assays were performed as described above.
Inhibition of Cell Adhesion
The A172 glioma cells (3 ϫ 10 4 ) were incubated with monoclonal antibodies (10 g/ml) against various types of integrins or with GRGDSP or GRGESP hexapeptide (50 g/ml) at room temperature for 15 minutes and then seeded on 24-well tissue culture plates coated with purified human vitronectin (10 g/ml) or human plasma fibronectin (10 g/ml). After an additional 2 hours' incubation at 37˚C in a humidified atmosphere containing 5% CO 2 , the cells were viewed with a phase-contrast microscope (IX 70, Olympus) at a magnification of 200 and photographed.
Ultrafiltration of Human Serum
Dialyzed serum taken from a healthy volunteer was filtered through Centricon or Microcon centrifugal concentrators (Amicon) with various molecular weight cutoff membranes (3000, 10,000, 30,000, 50,000, and 100,000) according to the manufacturer's instructions. The retained material (300 g protein) was added to the lower compartments of the Boyden chambers, and cell migration assays were performed as described above.
Immunodepletion of Vitronectin
Immunodepletion of vitronectin was performed according to the method described in a previous report. 7 Human serum from a normal volunteer was mixed overnight at 4˚C with sheep anti-human vitronectin IgG-protein G-Sepharose conjugate or control sheep IgG-protein G-Sepharose conjugate, after which the mixture was centrifuged to sediment the Sepharose beads. This procedure was repeated seven more times, using fresh sheep anti-vitronectin antibody (IgG)-Sepharose conjugate or control sheep IgG-Sepharose conjugate for each step. The vitronectin-depleted serum was separated on a 10% polyacrylamide gel under reducing conditions and electrically transferred to a Trans-Blot nitrocellulose membrane (Bio-Rad), blocked with 3% bovine serum albumin, and subjected to immunoblotting with mouse anti-human vitronectin antibody. The bound antibodies were visualized with anti-mouse IgG-alkaline phosphatase conjugate (Promega) and BCIP/NBT color development substrate (Promega). The immunoblot was scanned with a GT-9500 flat scanner (Epson) and analyzed with National Institutes of Health image software as described previously. 34 
Measurement of Vitronectin in Human CSF
Vitronectin levels in CSF were measured in duplicate using a Vitronectin EIA Kit (Takara) according to the manufacturer's instructions.
Results
Promotion of Glioma Cell Migration by Human Sera
We obtained serum samples from eight patients with gliomas, one patient with a pituitary adenoma (as a benign tumor control), and four healthy volunteers and examined the effects of these samples on glioma cell migration using Boyden chambers. We found that approximately 5 to 8% of the cells seeded in the upper chambers had migrated to the lower, serum-containing chambers after 20 hours. In contrast, few glioma cells migrated to the lower chamber when serum was absent (Fig. 1A) . The experiments were performed in the presence of 5 mM hydroxyurea, which completely inhibited cell growth (data not shown); thus, cell growth did not contribute to the observed effects. The ability to promote cell migration differed among the various serum samples, but there was not a substantial difference between sera from patients with glioma and the control samples from healthy volunteers.
Migration Promoted by a High-Molecular-Weight Protein
To identify the major factor in human serum that pro-motes glioma cell migration, we examined the effects of treating the serum by heat inactivation and trypsinization. Heat inactivation and trypsinization inhibited cell migration toward serum by 99% and 55%, respectively (Fig. 1B) .
These results suggest that a protein is the major factor in serum that promotes glioma cell migration.
To define the molecular weight of the major factors, we subjected the serum to ultrafiltration through membranes The components retained following filtration through membranes with molecular-weight cutoffs of 3000, 10,000, 30,000, or 50,000 had full activity in the Boyden chamber assay (Fig. 1C) . In contrast, the serum fraction retained after ultrafiltration though a 100,000 molecular-weight cutoff membrane had a reduced ability to promote glioma cell migration (Fig. 1C) . These results indicate that one of the major factors in serum that promotes glioma cell migration is a protein with a molecular weight above 50 kD.
Inhibit Glioma Cell Migration by Antibodies to ␣v or ␣v␤5 Integrins and RGD-Containing Peptides
We focused our attention on fibronectin and vitronectin because they are high-molecular-weight extracellular matrix proteins abundant in human serum. 23, 27 Using flow cytometry, we previously found that A172 human glioma cells express integrin subunits ␣5 and ␣v. 8 To determine which integrin receptors are involved in the interaction with fibronectin and vitronectin, we examined the effects of function-blocking monoclonal antibodies against different integrin subunits or complexes on the adhesion and spreading of A172 glioma cells ( Fig. 2A and B) . Cell spreading on vitronectin-coated substrates was almost completely blocked by antibodies against the ␣v subunit or the ␣v␤5 complex ( Fig. 2A) but not by antibodies against the ␣5 subunit or the ␣v␤3 complex. In contrast, cell spreading on fibronectin was selectively inhibited by an antibody against the ␣5 subunit (Fig. 2B) . The inability of anti-␣v␤3 antibodies to inhibit the adhesion and spreading of A172 cells on vitronectin could be due to a very low surface expression of integrin ␣v␤3, as indicated by our previous flow cytometric analysis. 8 In addition, the RGD-containing hexapeptide GRGDSP inhibited A172 cell spreading on vitronectin ( Fig. 2A) but did not affect cell spreading on fibronectin (Fig. 2B) . These results indicate that adhesion of A172 glioma cells to vitronectin is mediated by integrin ␣v␤5 in an RGD-dependent manner and that adhesion to fibronectin is mediated by an integrin containing an ␣5 subunit.
On the basis of these results, we examined the effect of the RGD peptide and the integrin-neutralizing antibodies on migration of glioma cells toward normal human serum (Fig. 2C) . Migration of glioma cells towards serum was substantially inhibited by function-blocking anti-␣v (90%) and anti-␣v␤5 (80%) monoclonal antibodies as well as by the RGD peptide (90%) (Fig. 2C) , whereas the anti-␣v or anti-␣v␤3 antibodies and the control peptide lacked significant effects. The effects of the anti-␣v and anti-␣v␤5 antibodies and the RGD peptide were not due to inhibition of adhesion to the membranes in the Boyden chambers because the A172 cells showed full attachment and spreading and a normal morphology after 20 hours in all samples examined (Fig. 2D) . Human serum-induced migration of T98G human GBM cells was also completely blocked by
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Effect of vitronectin on glioma cell migration the antibody to integrin ␣v but not by the antibody to integrin ␣5 (data not shown). These results indicated that disruption of the interaction between vitronectin and glioma cells inhibits the serum-induced migration of glioma cells.
Effect of Depletion of Serum Vitronectin on Glioma Cell Migration
To confirm that vitronectin is a major serum factor that promotes glioma cell migration, we examined the effect of depleting it from the serum. Immunodepletion of vitronectin from normal human serum was carried out by repeated immunoprecipitation. 7 Immunoblotting confirmed that this treatment reduced the concentration of vitronectin in serum by approximately 50% (Fig. 3A) . This 50% reduction in vitronectin caused a substantial reduction (~ 70%) in the ability of serum to promote A172 cell migration. Furthermore, this inhibition was reversed in a dose-dependent manner by the addition of exogenous vitronectin to the lower chamber (Fig. 3B) . Also, human serum-induced migration of T98G human glioma cells was inhibited by the depletion of vitronectin, and this inhibition was similarly reversed by the addition of vitronectin (Fig. 3C) . These results confirmed that vitronectin is one of the major factors in human serum that promote the migration of glioma cells.
Measurement of Vitronectin in the CSF of Patients With Glioma and Inhibition of CSF-Induced Cell Migration by Anti-Integrin Antibodies
Because glioma tissues lie adjacent to the CSF, we sus- pected that vitronectin in the CSF can also enhance the motility of glioma cells. Although it is well known that vitronectin is abundant in human serum, few investigators have reported examining vitronectin levels in human CSF. Hence, we performed an enzyme-linked immunosorbent assay to measure vitronectin in the CSF from three patients with gliomas (anaplastic astrocytoma, gliomatosis cerebri, and GBM) and two patients who did not have neoplastic disease (Table 1) . We found detectable levels of vitronectin in all CSF samples tested, but the concentration was much (~ 1000-fold) lower in CSF than in serum. In Case 1, the CSF was collected when there was no sign of tumor recurrence and when the patient was stable. In Case 2, lumbar puncture was performed when there was no sign of tumor recurrence, and CSF was later collected from the postoperative cavity in the brain when the tumor recurred in the adjacent brain parenchyma. In Case 3, CSF was collected via lumbar puncture and from the postoperative cavity in the brain when there was no sign of tumor recurrence. In the Boyden chamber assay, human CSF, except for that collected from the brain cavity, revealed much weaker capacity to promote cell motility than human serum. The CSF collected from the postoperative cavity in the brain had a higher concentration of vitronectin and greater chemotactic activity (Fig. 4A , Table 1 ). Cell motility was enhanced in a dose-dependent manner by the addition of CSF from Case 2 (Fig. 4A) . These results suggest that CSF that contains a higher concentration of vitronectin has a greater capacity to promote cell motility. Therefore, we examined the effect of antibodies to integrin ␣5, ␣v, or ␣v␤5 on migration induced by CSF obtained in the patient in Case 2. We found that cell migration was substantially reduced by the antibodies to ␣v or ␣v␤5 integrins, which block the interaction of vitronectin with A172 glioma cells, but that migration was unaffected by the anti-␣5 antibody, which blocks the interaction of glioma cells with fibronectin (Fig. 4B) . These results imply that vitronectin is one of the major factors in the CSF that promotes the migration of glioma cells.
Discussion
The authors of many studies have investigated the factors that promote glioma cell migration to help elucidate the molecular basis of the invasiveness of these tumors. Previous reports on the chemotactic migration of glioma cells have demonstrated that they migrate toward lysophosphatidic acid-Rho A activating factor 20, 28 or stromal derived factor-1␣, whose specific receptor, CXCR4, is expressed on the surface of glioma cells. 35 In addition, epidermal growth factor has been reported to be the strongest promoter of migration amongst the growth factors present in serum. 5 In this study, we showed that a major migrationpromoting factor in serum is a heat-inactivated, trypsincleavable protein with a molecular weight greater than 50 kD. These characteristics contrast with those of many growth factors, chemokines, and lipids that can induce migration. Furthermore, using integrin-neutralizing antibodies, RGD-containing peptides, and vitronectin-depleted serum, we showed that vitronectin (molecular weight 65-75 kD) is one of the major factors in human serum that promotes the migration of glioma cells. The ability to promote cell migration differed for the various serum samples tested, but there was no substantial difference among sera from patients with GBM, anaplastic astrocytoma, or pituitary adenoma and normal controls. It has been reported that neoplastic astrocytes in vivo and in vitro showed increased expression of integrin ␣v subunit and that benign tumor cells, including cells derived from pituitary adenoma and meningioma, showed the same integrin pattern as their normal counterparts. 21 Therefore, it is possible that in patients with glioma, upregulation of receptors that interact with vitronectin leads to promotion of glioma cell migration by serum.
We also found that the promotion of glioma cell migration by CSF from patients with glioma corresponded to the amount of vitronectin in the sample. Again, blocking the vitronectin-integrin interaction greatly reduced CSF-induced cell migration. These findings suggested that vitronectin is an important promoter of glioma cell migration not only in serum but also in CSF, although our results were valid for only two glioma cell lines and have not been validated with cells from glioma specimens in vivo.
Angiogenesis and high vessel wall permeability are often observed in malignant glioma tissues, 1 ) were plated on the upper filters and allowed to migrate toward lower chambers that contained CSF taken from three patients with glioma and two patients with nonneoplastic disease (see Table 1 for details). In Case 2 only, the test was performed using three different amounts of CSF from the same site. After 20 hours, the number of cells that migrated to the lower membranes was counted. B: Graph showing that cell migration toward CSF was inhibited by the addition of antibodies to ␣v or ␣v␤5 but not ␣5 integrins. The CSF used in this analysis was obtained from the brain cavity of the patient in Case 2; 100 l was placed in each lower chamber of the assay apparatus. The results are expressed as the total number of cells that migrated to the lower filters. *p Ͻ 0.01 compared with results obtained using control IgG.
brain barrier may promote glioma cell invasion. 25 Therefore, it is possible that vitronectin leaking from highly permeable vessels within glioma tissue promotes the migration of glioma cells in vivo.
Both fibronectin and vitronectin are abundant in human serum and enhance the adhesion and migration of various cell types in vitro. Furthermore, several reports indicate that two other factors play important roles in invasion in gliomas: 1) the interaction of integrins on glioma cell surfaces with extracellular matrix molecules, and 2) proteases, including matrix metalloproteinases, which degrade extracellular matrix components. 2, 14, 22, 24, 32, 33 In the current studies, we focused on the role of fibronectin and vitronectin in human serum-or CSF-induced cell migration. Interestingly, blocking the fibronectin-integrin interaction had less of an effect on serum-or CSF-induced migration than blocking the vitronectin-integrin interaction. Immunohistochemical studies have shown that fibronectin or laminins are present in the blood vessels of glioma tumors, 6, 18, 26 whereas vitronectin 12, 13, 18 and tenascin 18, 21 are associated with tumor cells in the tumor parenchyma. Thus, it is possible that molecules surrounding tumor cells, including vitronectin, promote cell motility in the glioma tissue.
We speculate that there are two vitronectin sources that account for the accumulation of this protein in glioma tissue: 1) Vitronectin may be produced by the glioma cell itself, as reported by Gladson et al. 12, 13 and Mahesparan et al. 18 based on immunohistochemical studies and in situ hybridization.
2) It may be leaked through serum from tumor vessels surrounding gliomas, given that serum contains a large amount of vitronectin 23 and vascular permeability in tumor tissues is high. 25 Our present results indicate that a partial disruption of the interaction between vitronectin and glioma cells can strongly suppress human serum-or CSF-induced glioma cell migration and invasion. Blocking the interaction between vitronectin and integrin on glioma cells could therefore represent a new approach for preventing tumor cell invasion. In vivo experiments using mouse glioma models show that intracranial treatment with an RGD-containing peptide can suppress brain tumor growth by inducing the apoptosis of both brain tumor and brain capillary cells 30 and that this peptide can prolong survival. 3 Vitronectin has only one cell-binding site (RGD sequence), 29 and the current studies confirm that RGD peptides strongly inhibit the interaction of glioma cells with vitronectin.
Conclusions
Our results suggest that vitronectin is an important promoter of glioma cell migration not only in serum but also in CSF.
